As trials for IL-6 blocking agents like TCZ and sarilumab did not meet their primary endpoints in AS (33), the approach of initially adding a TNF-blocking agent in those AS patients who develop AA amyloidosis seems rational. The gene discussed is TNF; the disease is AA amyloidosis.